Results 191 to 200 of about 98,834 (296)

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz   +8 more
wiley   +1 more source

Is regional atrial strain a useful surrogate of regional atrial fibrosis in atrial cardiomyopathy? [PDF]

open access: yesEur Heart J Imaging Methods Pract
Lee AWC   +17 more
europepmc   +1 more source

Neurokinin‐1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose The pathogenesis of type 2 diabetes mellitus (T2DM)‐induced cardiomyopathy involves cardiac fibrosis that leads to diastolic dysfunction. We established that replacement of lost substance P (SP) that occurs in T2DM reduces cardiac fibrosis and decreases inflammation in T2DM mice and non‐human primates.
Alexander Widiapradja   +11 more
wiley   +1 more source

Multimodal Evaluation of Arrhythmogenic Substrate Predicts Atrial Fibrosis and Atrial Fibrillation Recurrence After Catheter Ablation. [PDF]

open access: yesJ Clin Med
Minciună IA   +12 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Increased Left Ventricular Mass Index and Atrial Volume Index Are Associated with Atrial Fibrosis in Patients with Atrial Fibrillation. [PDF]

open access: yesJ Clin Med
Manole S   +10 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena   +5 more
wiley   +1 more source

Non-Invasive Prediction of Atrial Fibrosis Using a Regression Tree Model of Mean Left Atrial Voltage. [PDF]

open access: yesBiomedicines
Ibero J   +7 more
europepmc   +1 more source

Concurrent validity and agreement of Bayley‐4, AIMS, and HINE assessments in 1‐year‐old children

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
In this cross‐sectional study of children around 1‐year‐old, the Bayley‐4 showed concurrent validity and moderate to substantial agreement with the AIMS and the HINE in both clinical and home settings. Abstract Aim To examine concurrent validity between the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley‐4) gross motor subtest ...
Weiyang Deng   +14 more
wiley   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy